110 filings
8-K
ALLK
Allakos Inc.
27 Jan 25
Regulation FD Disclosure
7:07am
8-K
ALLK
Allakos Inc.
27 Jan 25
Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring
7:05am
8-K
ALLK
Allakos Inc.
18 Nov 24
Entry into a Material Definitive Agreement
4:45pm
8-K
ALLK
Allakos Inc.
6 Nov 24
Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results
4:07pm
8-K
ALLK
Allakos Inc.
10 Oct 24
Regulation FD Disclosure
4:07pm
8-K
66pmwj3a7ox7xcq3bpo
10 Oct 24
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
4:04pm
8-K
3obml6 4c4
16 Aug 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:00am
8-K
9pbz ebwiealna
7 Aug 24
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
4:06pm
8-K
vqfiqlitv9qsgcgb
25 Jun 24
Regulation FD Disclosure
4:22pm
8-K
fmo6fq
25 Jun 24
Other Events
4:20pm
8-K
o10ogb52ntpdbq41buf
28 May 24
Submission of Matters to a Vote of Security Holders
7:20am
8-K
oef0zcrevwrq
28 May 24
Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
7:15am
8-K
gayf 9aj25fdvwhln
9 May 24
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
4:06pm
8-K
6jxr7pbx36pvb3u5z35
23 Apr 24
Departure of Directors or Certain Officers
5:10pm
8-K
gjc199ii53
14 Mar 24
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:15pm
8-K
n9k69icdngl
26 Feb 24
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
7:05am
8-K
h6d16 c9uihgkmeslv
12 Feb 24
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
7:07am
8-K
dbk30p
2 Feb 24
Regulation FD Disclosure
4:05pm
8-K
m4hifp28he8 bj
16 Jan 24
Regulation FD Disclosure
6:17pm
8-K
omebyu
16 Jan 24
Allakos Announces a Restructuring to Focus on Development of AK006
5:00pm